Craig A. Johnson has been a Director of La Jolla since October 2013. Mr. Johnson serves on the boards of directors of several life science companies. He is currently a director for Heron Therapeutics, Inc., a pharmaceutical company developing treatments for cancer and pain, as well as Mirati Therapeutics, Inc., a biopharmaceutical company. Mr. Johnson also served as a past director of Adamis Pharmaceuticals Corporation, a biotechnology company, from 2011 to 2014, as well as Ardea Biosciences, Inc., a pharmaceutical company focused on treatments for inflammatory diseases and cancer, from 2008 until its sale to AstraZeneca PLC in 2012. From 2011 to 2012, he was Chief Financial Officer of PURE Bioscience, Inc., a biotechnology company, and from 2010 to 2011, he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President for a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994, Mr. Johnson held senior financial positions with several early-stage technology companies and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan – Dearborn.
|Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts|